Individuals with chronic kidney disease (CKD) are at an increased risk of heart failure; conversely, kidney function decline is common in individuals with heart failure (HF). Sodium–glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression and hospitalization for heart failure, both in patients with CKD and in patients with HF. This session addresses the beneficial effects of SGLT2 inhibitors for the treatment of CKD and HF in older adults

Continuing Education Instructions and Disclosure Information:

Contact hours available until 3/23/2026.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
There are no Planning Committee disclosures to declare.

Speakers Disclosures:
There are no speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Gerontological Advanced Practice Nurses Association (GAPNA).

Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Anthony J. Jannetti, Inc. is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5387.

Learning Outcome:
After completing this learning activity, participants will be able to list at least two beneficial effects of SGLT2 inhibitors for the treatment of CKD and HF in older adults

Lynn Sheppard MSN, RN, CHFN, ANP-BC

Appearances